Current views on etiopathogenesis, clinical manifestations and treatment of pyodermas in children
https://doi.org/10.21518/2079-701X-2020-1-118-129
Abstract
Pyoderma - a pustular skin disease caused by pyogenic bacteria, - golden staphylococcus and pyogenic streptococcus [1], belongs to the group of diseases of interdisciplinary character, because it is found in the practice of therapists, infectious disease specialists, pediatricians, surgeons, and others. [2]. Pyodermas are one of the most widespread dermatoses in Russia and abroad, accounting for 17 to 43% of the total structure of skin pathology [3]. Changes in macroorganism reactivity, pathogenicity of microorganisms and unfavorable influence of environment determine pathogenetic mechanisms of pyodermas development. In this article, each of the listed factors for the development of the skin infection process, clinical forms and complications are considered in detail. Pyodermas caused by S. aureus are the most frequently encountered in the practice of a pediatrician. To date, the clinical picture of staphylodermia in children is very diverse and includes both localized and widespread forms, and may be characterized by a generalized flow threatening the life of the patient. The most dangerous forms of pyodermas in pediatric practice are Ritter’s exfoliating dermatitis and Staphylococcal scalded skin syndrome. This article describes the general principles of diagnosis and treatment of pyodermas. Emphasis is placed on the description of antibacterial therapy under conditions of continuous growth of antibiotic resistance. Taking into account the high prevalence of the disease among children, the age features and variants of the course of pustular diseases in this group of patients are analyzed in detail.
About the Authors
O. B. Tamrazova
People’s Friendship University of Russia; Children’s City Clinical Hospital named after Z.A. Bashlyaeva
Russian Federation
Russian Federation
Olga B. Tamrazova - Dr. of Sci. (Med), Professor of the Department of Dermatovenerology, Faculty of Advanced Training of medical workers, PFUR; dermatovenerologist, ChCCH named after Z.A. Bashlyaeva.
6, Miklukho-Maklaya St., Moscow, 117198; 28, Geroev Panfilovtsev St., Moscow, 125373
E. A. Shmeleva
People’s Friendship University of Russia
Russian Federation
Russian Federation
Evgeniya A. Shmeleva - Resident of the Department of Dermatovenerology, Faculty of Advanced Training of medical workers.
6, Miklukho-Maklaya St., Moscow, 117198
A. K. Mironova
Children’s City Clinical Hospital named after Z.A. Bashlyaeva
Russian Federation
Russian Federation
Alena K. Mironova - Cand. of Sci. (Med), head of the Rehabilitation Centre for children under 3 years of age.
28, Geroev Panfilovtsev St., Moscow, 125373
N. F. Dubovets
Children’s City Clinical Hospital named after Z.A. Bashlyaeva
Russian Federation
Russian Federation
Nataliya F. Dubovets - paediatrician, head of reception
28, Geroev Panfilovtsev St., Moscow, 125373
References
1. Pereira L.B. Impetigo - review. An Bras Dermatol. 2014;89(2):293-299. doi: 10.1590/abd1806-4841.20142283.
2. Mironov A.Yu., Zhilina S.V., Dmitrenko O.A., Avilova N.D. Microbiological monitoring of pathogens of Pyo-inflammatory diseases of the skin and soft tissues and their antibiotic resistance. National priorities of Russia. 2011;2(5):204-205.
3. Buxton PK. ABC of dermatology. Bacterial infection. Br Med J (Clin Res Ed). 1988;296(6616):189-192. doi: 10.1136/bmj.296.6616.189.
4. Bowen A.C., Mahe A., Hay RJ., Andrews R.M., Steer A.C., Tong S.Y., Carapetis J.R. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One. 2015;28;10(8):e0136789. doi: 10.1371/journal.pone.0136789.
5. Galli L., Venturini E., Bassi A., et al. Common Community-acquired Bacterial Skin and Soft-tissue Infections in Children: an Intersociety Co nsensus on Impetigo, Abscess, and Cellulitis Treatment. Clin Ther. 2019;41(3):532-551.e17. doi: 10.1016/j.clinthera.2019.01.010.
6. Tong S.Y, Davis J.S., Eichenberger E., Holland T.L., Fowler VG. Jr. Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. Clin Microbiol Rev. 2015;28(3):603-661. doi: 10.1128/CMR.00134-14.
7. Luby S.P., Agboatwalla M., Feikin D.R., Painter J., Billhimer W., Altaf A., et al. Effect of handwashing on child health: a randomized controlled 14. trial. Lancet. 2005;(366):225-33. doi: 10.1016/S0140-6736(05)66912-7.
8. Oh J., Byrd A.L., Deming C. et al. Biogeography and individuality shape function in the human skin metagenome. Nature. 2014;(514):59-64. doi: 10.1038/nature13786.
9. Grice E.A., Kong H.H., Conlan S. et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;325(5943):944-945. doi: 10.1126/science.1171700.
10. Lancefield R.C., Freimer E.H. Type-specific polysaccharide antigens of group B streptococci. J 16. Hyg (Lond). 1966;(64):191-203. doi: 10.1017/S0022172400040456.
11. Bessen D.E., Kumar N., Hall G.S. et al. Whole-genome association study on tissue tropism phenotypes in group A Streptococcus. J Bacteriol. 2011;193(23):6651-6663. doi: 10.1128/JB.05263-11.
12. Tamrazova O.B. Silver-containing drugs in treatment of pyoderma. Klinicheskaya derma-tologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2014;12(3):49-57. (In Russ.) Available at: https://www.mediasphera.ru/issues/kliniches-kaya-dermatologiya-i-venerologi-ya/2014/3/031997-2849201438.
13. Barnard E., Li H. Shaping of cutaneous function by encounters with commensals. J Physiol. 2017;595(2):437-450. doi: 10.1113/JP271638.
14. Sakr A., Bregeon F., Mege J.-L., et al. Staphylococcus aureus Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections. Front Microbiol. 2018;(9):2419. doi: 10.3389/fmicb.2018.02419.
15. Mulcahy M.E., Geoghegan J.A., Monk I.R., O'Keeffe K.M., Walsh EJ., Foster TJ., et al. Nasal colonisation by Staphylococcus aureus depends upon clumping factor binding to the squamous epithelial cell envelope protein loricrin. PLoS Pathog. 2012;8(12):e1003092. doi: 10.1371/journal.ppat.1003092.
16. Durupt F., Mayor L., Bes M., Reverdy M.E., Vandenesch F., Thomas L., et al. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol. 2007;(157):1161-1167. doi: 10.1111/j.1365-2133.2007.08197.x.
17. Noble W.C. Skin bacteriology and the role of Staphylococcus aureus in infection. Br J Dermatol. 1998;(139):9-12. doi: 10.1046/j.1365-2133.1998.1390s3009.x.
18. Oumeish I., Oumeish O.Y., Bataineh O. Acute bacterial skin infections in children. Clin Dermatol. 2000;(18):667-678. doi: 10.1016/s0738-081x(00)00156-5.
19. Vlassova N., Han A., Zenilman J.M., James G., Lazarus G.S. New horizons for cutaneous microbiology: the role of biofilms in dermatological disease. Br J Dermatol. 2011;(165):751-759. doi: 10.1111/j.1365-2133.2011.10458.x.
20. Chiller K., SeLkin B.A., Murakawa GJ. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc. 2001;(6):170-174. doi: 10.1046/j.0022-202x.2001.00043.x.
21. MiajLovic H., Fallon P.G., Irvine A.D., Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol. 2010;126(6):1184-1190.e3. doi: 10.1016/j.jaci.2010.09.015.
22. Manders S.M. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol. 1998;(39):383-398. doi: 10.1016/s0190-9622(98)70314-7.
23. Nishifuji K., Shimizu A., Ishiko A., Iwasaki T., Amagai M. Removal of amino-terminal extracellular domains of desmoglein 1 by staphylococcal exfoliative toxin is sufficient to initiate epidermal blister formation. J Dermatol Sci. 2010;59(3):184-191. doi: 10.1016/j.jdermsci.2010.07.010.
24. Jevons M.P. Celbenin-resistant staphylococci. Br Med J. 1961;(1):124-125. doi: 10.1136/bmj.1.5219.124-a.
25. Lakhundi S., Zhang K. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin Microbiol Rev. 2018;31(4). pii: e00020-18. doi: 10.1128/CMR.00020-18.
26. Feeler A., Kadlec K., Wang Y., Zhang WJ., Wu C., Shen J., Schwarz S. Small Antimicrobial Resistance Plasmids in Livestock-Associated Methicillin-Resistant Staphylococcus aureus CC398. Front Microbiol. 2018;(9):2063. doi: 10.3389/fmicb.2018.02063.
27. Otto M. Community-associated MRSA: what makes them special? Int J Med Microbiol. 2013;303(6-7):324-330. doi: 10.1016/j.ijmm.2013.02.007.
28. Carrol J.A. Common bacterial pyodermas. Taking aim against the most likely pathogens. Postgrad Med, 1996;(100):311-313, 317-322. doi: 10.3810/pgm.1996.09.84.
29. Chebotaryov V.V., Tamrazova O.B., Chebotaryova N.V., Odinets A.V. Dermatovenerology. Moscow: GEOTAR-Media; 2013. 584 p.
30. Tamrazova O.B. Overcoming antibiotic resistance in treatment of pyoderma. Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2014;12(6):64-73. (In Russ.) doi: 10.17116/klin-derma2014664-73.
31. Kasihina E.I. Application of broad-spectrum antibiotic combinations for topical treatment of pyoderma. Consilium Medicum. Dermatology (Suppl) 2015;17(2):5-10. (In Russ.) Available at: https://dermatology.con-med.ru/upload/iblock/8fb/derma2_1.pdf.
32. Koning S. et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;(1):CD003261. doi: https://doi. org/10.1002/14651858.CD003261.pub3.
33. Hartman-Adams H. et al. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90(4):229-235. Available at: https//www.ncbi.nlm.nih.gov/pubmed/25250996.
34. Petry V., Bessa G.R., Poziomczyck C.S., Oliveira C.F., Weber M.B., Bonamigo R.R., d’Azevedo P.A. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012;87(5):729-734. doi: 10.1590/s0365-05962012000500010.
35. Vogel A., Lennon D., Best E., Leversha A. Where to from here? The treatment of impetigo in children as resistance to fusidic acid emerges. N Z Med J. 2016;129(1443):77-83.
36. BPAC New Zealand. Topical antibiotics: very few indications for use. Best Practice Journal. 2014;(64). Available at: https://bpac.org.nz/BPJ/2014/October/topical-antibiotics.aspx.
37. BPAC New Zealand. Should I prescribe a topical antiseptic cream instead of topical antibiotic for minor skin infections? Best Practice journal. 2015;(68).
38. Vogel A.M., Lennon D.R., Gray S., et al. Registered nurse assessment and treatment of skin sepsis in New Zealand schools: the development of protocols. N Z Med J. 2013;126(1380):27-38. Available at: https//www.ncbi.nlm.nih.gov/pubmed/24126747.
39. Baker M.G., Barnard L.T., Kvalsvig A. et al. Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet. 2012;(379):1112-1119. doi: 10.1016/S0140-6736(11)61780-7.
40. Koning S., van der Wouden J.C., Chosidow O., Twynholm M., Singh K.P., Scangarella N., et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized doubleblind multicentre placebo-controlled trial. Br J Dermatol. 2008;(158):1077-1082. 10.1111/j.1365-2133.2008.08485.x.
41. Leclercq R., Bismuth R., Casin I., Cavallo J.D., Croize J., Felten A., Goldstein F., Monteil H., Ouentin-Noury C., Reverdy M., Vergnaud M., Roiron R. In Vitro Activity of Fusidic Acid Against Streptococci isolated form Skin and Soft Tissue Infections. J Antimicrob Chemother. 2000;45(1):27-29. doi: https://doi.org/10.1093/jac/45.1.27.
42. Hall S. Existing drug will cure hospital superbug MRSA, say scientists. The Guardian. 17 January 2007. Accessed 2008-01-17. Available at: https://www.theguardian.com/society/2007/jan/17/nhs.health.
43. Castanheira M., Mendes R.E., Rhomberg P.R., Jones R.N. Activity of fusidic acid tested against contemporary Staphylococcus aureus collected from United States hospitals. Infectious Diseases Society of America. 48th Annual Meeting. 2010;Abstract 226. Available at: https://idsa.confex.com/idsa/2010/webpro-gram/Paper3192.htm.
44. Rortveit S., Skutlaberg D. H., Langeland N., Rortveit G. Impetigo in a population over 8,5 years: incidence, fusidic acid resistance and molecular characteristics. J Antimicrob Chemother. 2011;66(6):1360-1364. doi: 10.1093/jac/dkr102.
45. Sergeev A.Y., Burceva G.N., Sergeev V.Y. Cutaneous staphylococci: fighting the bacterial resistance in treatment of common inflammatory skin disease. Immunopatologiya, allergologi-ya, infektologiya = Immunopathology, allergology, infectology. 2014;(4):42-55. (In Russ.) http://www.immunopathology.com/en/article.php?carticle=171.
46. Jappe U., Schnuch A., Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995-1999. Br J Dermatol. 2003;(149):87-93. doi: 10.1046/j.1365-2133.2003.05290.x.
47. Furfaro L.L., Payne M.S., Chang BJ. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol. 2018;(8):376. doi: 10.3389/fcimb.2018.00376.
Review
For citations:
Tamrazova OB, Shmeleva EA, Mironova AK, Dubovets NF. Current views on etiopathogenesis, clinical manifestations and treatment of pyodermas in children. Meditsinskiy sovet = Medical Council. 2020;(1):118-129. (In Russ.) https://doi.org/10.21518/2079-701X-2020-1-118-129
Views:
1016
Email this article 